Bank Of New York Mellon Corp Tarsus Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$14.12 - $18.72 $836,624 - $1.11 Million	59,251 New	59,251 $868,000
Q3 2022 Nov 14, 2022	BUY	$14.08 - $18.5 $134,689 - $176,971	9,566 Added 21.46%	54,148 $927,000
Q2 2022 Aug 15, 2022	BUY	$11.08 - $19.08 $215,738 - $371,506	19,471 Added 77.54%	44,582 $651,000
Q1 2022 May 11, 2022	SELL	$14.49 - $24.28 $2,535 - $4,249	-175 Reduced 0.69%	25,111 $423,000
Q4 2021 Feb 11, 2022	BUY	$21.21 - $29.68 $16,183 - $22,645	763 Added 3.11%	25,286 $569,000
Q3 2021 Nov 12, 2021	BUY	$21.45 - $29.22 $63,277 - $86,199	2,950 Added 13.67%	24,523 $529,000
Q2 2021 Aug 11, 2021	BUY	$27.16 - $38.59 $165,648 - $235,360	6,099 Added 39.41%	21,573 $625,000
Q1 2021 May 13, 2021	SELL	$27.37 - $47.25 $80,549 - $139,056	-2,943 Reduced 15.98%	15,474 $498,000
Q4 2020 Feb 09, 2021	BUY	$19.17 - $49.62 $353,053 - $913,851	18,417 New	18,417 $761,000

170

43.3M

484K

4.1K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.4B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.